Pay in 4 interest-free payments of $9.00 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
inducing epigenetic changes in leukemia cells and the expression of promoter methylated genes
90% PEG300
is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer
Dibirdik I
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor
GSK-J1 - H3K27 Histone Demethylases UTX and JMJD3 Inhibitor. CAS# 1373422-53-7 size:2mg solid inducing epigenetic changes in leukemiaGSK J1, CAS No. 1373422 53 7, is the first selective and potent inhibitor of the H3K27 histone demethylases UTX and JMJD3. H3K27 methylations play important roles in regulating gene expression through the polycomb repressive complex (PRC1 or PRC2). This epigenetic mark can be demethylated by lysine demethylase (KDM) UTX and JMJD3, which play important roles in cellular differentiation, development and cancer. In relevant biological assays, GSK J1 was
US$ 390.50
US$ 450.50
US$ 152.00
US$ 385.00
US$ 209.00